Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Biochim Biophys Acta. 2013 Jun 28;1832(12):10.1016/j.bbadis.2013.06.012. doi: 10.1016/j.bbadis.2013.06.012

Figure 4.

Figure 4

Glycogen synthase kinase 3 beta and Alzheimer’s disease pathology. Amyloid beta-induced elevated GSK3β activity is a key event in abnormal APP processing, increased Aβ production, and phosphorylation of tau and synaptic pathology in AD. GSK3β is proposed to activate VDAC1 phosphorylation that ultimately leading to mitochondrial dysfunction and synaptic damage in AD